News for 'Sun Pharmaceuticals'

Trump doubles tariff on India to 50% for buying Russian oil

Trump doubles tariff on India to 50% for buying Russian oil

Rediff.com6 Aug 2025

US President Donald Trump on Wednesday slapped an additional 25 per cent tariff on goods coming from India as penalty for New Delhi's continued buying of Russian oil.

Indian Pharma Gets Relief from Trump's Tariffs

Indian Pharma Gets Relief from Trump's Tariffs

Rediff.com4 Apr 2025

Indian drugmakers supply 47 per cent of the generic medicine requirements in the US, and tariffs would have increased prices in the US domestic market for patients, who are already dealing with drug shortages.

'Worst setback since 1962': Cong slams Modi's 'DDLJ doctrine' on China

'Worst setback since 1962': Cong slams Modi's 'DDLJ doctrine' on China

Rediff.com4 Aug 2025

The Congress party has accused the Modi government of a 'deny, distract, lie, and justify' (DDLJ) policy regarding China, alleging territorial setbacks and misplaced economic priorities.

25% Donald Trump tariff likely to weigh on pharma margins: Analysts

25% Donald Trump tariff likely to weigh on pharma margins: Analysts

Rediff.com12 Aug 2025

If pharmaceutical exports from India to the US come under a 25 per cent tariff bracket, the impact on earnings before interest, tax, depreciation and amortisation (Ebitda) could be around 5 per cent, felt analysts. This is after assuming that about 75 per cent of the tariff would be passed on.

'India-China Won't Go Back To What It Was'

'India-China Won't Go Back To What It Was'

Rediff.com4 Sep 2025

'What's currently underway is not a 'reset'.' 'What needs to be arrived at is a new balance.'

Trump's Russian Roulette Over India's Oil Supply

Trump's Russian Roulette Over India's Oil Supply

Rediff.com5 Aug 2025

The trade relationship between India and the United States has been strained by the imposition of 25% tariff by the US on Indian goods.

Higher US tariffs may trim GDP growth by 30 bps: Barclays

Higher US tariffs may trim GDP growth by 30 bps: Barclays

Rediff.com31 Jul 2025

The 25 per cent US tariffs, plus a penalty for Russian imports, could dent India's GDP growth by 30 basis points in the current fiscal, but the higher duty is unlikely to significantly affect India's domestic demand-driven economy, Barclays said on Thursday. If the 25 per cent tariff, announced by US President Donald Trump on Wednesday, is implemented from August 1, the effective average US import tariff on Indian goods will rise to 20.6 per cent in trade-weighted terms, as per Barclays estimates.

Manufacturing dominated new projects in Q1, share at 10-quarter high

Manufacturing dominated new projects in Q1, share at 10-quarter high

Rediff.com21 Jul 2025

More than half of all new project announcements in the June 2025 quarter came from the manufacturing sector. Manufacturing projects worth around Rs 2.3 trillion were announced in the three-month period, accounting for 54 per cent of total new projects, according to data from the Centre for Monitoring Indian Economy (CMIE).

Telangana plant explosion toll rises to 36; FIR against factory mgmt

Telangana plant explosion toll rises to 36; FIR against factory mgmt

Rediff.com1 Jul 2025

The death toll from the explosion at the Sigachi Industries' pharma plant in Pashamylaram has risen to 35, police said on Tuesday.

These products account for over 50% of India's exports in FY25

These products account for over 50% of India's exports in FY25

Rediff.com16 May 2025

Agriculture, pharma, electronics, and engineering goods together accounted for over 50 per cent of India's merchandise exports in 2024-25, according to government data, highlighting the country's growing strength in diverse sectors amid efforts to boost manufacturing and value-added exports.

India Inc holds breath for Trump's new tariffs to kick in

India Inc holds breath for Trump's new tariffs to kick in

Rediff.com27 Feb 2025

Industry insiders in India warn that any such move in the pharmaceutical sector could be counterproductive for the US as it may face increased drug shortages if tariffs are imposed on such imports.

India Must Only Agree To A Deal If It Is A Win-Win

India Must Only Agree To A Deal If It Is A Win-Win

Rediff.com27 Aug 2025

To those who ask, "Is all this really worth it? Why can't domestic demand fill the gap?", it is important to remind them that only 13 economies since the Second World War have grown at 7 per cent or more for 25 years -- like India needs to. They all had one thing in common: Strong export growth underpinned by strong global engagement, explains Sajjid Z Chinoy.

Trump's Tariffs: Why India Needs To Be Strategic

Trump's Tariffs: Why India Needs To Be Strategic

Rediff.com12 Aug 2025

In trade negotiations, as in chess, sometimes you need to accept a temporary disadvantage to secure a better long-term position, points out Sonal Varma, chief economist (India and Asia ex-Japan) at Nomura.

This will Likely Shape the Future of Pharma Inc

This will Likely Shape the Future of Pharma Inc

Rediff.com8 Mar 2025

Indian pharmaceutical companies may have units abroad as part of "distributed manufacturing" across various locations, according to industry veterans. This may come about over the next five to 10 years.

A Deal Is Possible Only On Trump's Terms

A Deal Is Possible Only On Trump's Terms

Rediff.com31 Jul 2025

For India, the challenge is to strike a balance between tactical necessity and economic priorities, point out Pravin Krishna and Monil Sharma.

Sun Pharma Q4 profit down 19% at Rs 2,149.8 cr, revenue up 8%

Sun Pharma Q4 profit down 19% at Rs 2,149.8 cr, revenue up 8%

Rediff.com23 May 2025

India's largest drug maker Sun Pharmaceutical on Thursday posted a decline of 19 per cent year-on-year (Y-o-Y) for its consolidated net profit for the fourth quarter of the financial year 2025 (Q4FY25) at Rs 2,149.8 crore. Meanwhile, its revenue from operations rose by 8 per cent at Rs 12,958.8 crore.

India's June exports shrink but shipments to US zoom

India's June exports shrink but shipments to US zoom

Rediff.com16 Jul 2025

Merchandise exports to the US jumped 23.5 per cent year-on-year (Y-o-Y) to $8.3 billion in June, even as India's overall outbound shipments witnessed contraction during the month, according to the data released by the commerce department on Tuesday. The increase in outbound shipments to the US was largely driven by the rush among exporters to utilise America's pause on its plans to impose country-specific reciprocal tariffs.

Shortcuts Won't Build Industrial Capability

Shortcuts Won't Build Industrial Capability

Rediff.com28 Jul 2025

Any industrial policy is only as good as how it is applied and the other reforms that support it. This was as true 40 years ago as it is now, points out Debashis Basu.

Shell deepens India market reach through Raj Petro buy

Shell deepens India market reach through Raj Petro buy

Rediff.com4 Jul 2025

Global energy giant Shell has acquired Mumbai-based Raj Petro Specialities to deepen its foothold in the world's third biggest lubricants market in the world, a top company official said. Shell, which has already invested over $5 billion in India across the energy value chain -- from LNG import terminals and fuel stations to renewable energy and technology centres -- has acquired 100 per cent equity interest in Raj Petro Specialities Pvt Ltd from Germany's Brenntag Group.

'Fully agree with you': Modi, Meloni strike a chord at G7

'Fully agree with you': Modi, Meloni strike a chord at G7

Rediff.com18 Jun 2025

Prime Minister Narendra Modi held a series of bilateral meetings with his global counterparts on the margins of the G7 Summit in Kananaskis, with discussions focusing on a range of issues such as trade, investment, counter-terrorism and global challenges.

'Indian Markets To Outperform For Next 20 Years'

'Indian Markets To Outperform For Next 20 Years'

Rediff.com29 May 2025

'When you have the best market at your doorstep, international diversification is a distraction.'

Walmart to add 1 lakh MSMEs in next 3 years

Walmart to add 1 lakh MSMEs in next 3 years

Rediff.com19 Jun 2025

US-based retail giant Walmart will connect one lakh more MSMEs in the next three years to its supplier development programme in India, a company official said here on Thursday. The programme, Walmart Vriddhi, has partnered with Ideas to Impact Foundation (i2i), which will enable more MSMEs to expand their access to both national and international markets, helped by the combined strengths of Walmart's global supply chain and Flipkart's e-commerce capabilities.

Mithi river 'scam': ED raids Dino Morea's residence

Mithi river 'scam': ED raids Dino Morea's residence

Rediff.com6 Jun 2025

The fraud is alleged to have caused a Rs 65 crore loss to the Brihanmumbai Municipal Corporation (BMC).

'India Can Convert Tariffs Into Win-Win Situation'

'India Can Convert Tariffs Into Win-Win Situation'

Rediff.com11 Aug 2025

'It's important for India to think about areas where it wants the US to move.' 'We can be far more innovative in what we ask the US.' 'Given that there's a package deal, why not do it?'

Trump's tariffs: How will these sectors in India be impacted?

Trump's tariffs: How will these sectors in India be impacted?

Rediff.com2 Apr 2025

Goods from sectors, including agriculture, precious stones, chemicals, pharma, medical devices, electricals, and machinery may get impacted if the US will go ahead with imposing reciprocal tariffs on Indian products, according to experts. They said that these sectors could face additional customs duties from the Trump administration because of the high tariff differential or gap, which is the difference between the import duties imposed by the US and India on a product.

'Medicines are just one part of the solution'

'Medicines are just one part of the solution'

Rediff.com21 May 2025

'We are looking at what kind of products, diagnostics or other solutions we can offer to become a well-rounded player in a particular disease area globally.'

Can MFN Pricing Reshape India-US Pharma Equation?

Can MFN Pricing Reshape India-US Pharma Equation?

Rediff.com5 Jun 2025

US accounts for a large part of revenue for top Indian pharma companies like Gland Pharma (54 percent), Dr Reddy's (53 per cent), and Aurobindo Pharma (48 per cent).

India hasn't accepted UK 'data exclusivity' demand in FTA

India hasn't accepted UK 'data exclusivity' demand in FTA

Rediff.com12 May 2025

India has not accepted the demand of the UK for inclusion of a 'data exclusivity' provision in the free trade agreement, announced on May 6, in a bid to protect the interests of the domestic generic drugs industry, an official said. During the negotiations, the UK had asked to include this provision in the trade pact.

Sun Pharma stock up 2.15% as US court clears alopecia drug launch

Sun Pharma stock up 2.15% as US court clears alopecia drug launch

Rediff.com12 Apr 2025

Sun Pharmaceutical Industries stock ended 2.15 per cent higher on Friday after zooming by almost 5 per cent in the morning trade on the back of an announcement that a court ruling has cleared the deck for the India's largest pharmaceutical company to launch its alopecia drug Leqselvi in the United States.

Foreign brokerages stay cautious on India stock market

Foreign brokerages stay cautious on India stock market

Rediff.com10 Jun 2025

Foreign brokerages remain cautious on the road ahead for the Indian equity markets. Though analysts at Nomura have revised their March 2026 Nifty target to 26,140 levels from the earlier 24,970, but the upside from the current levels is a modest 6 per cent. BofA Securities, on the other hand, has not made any change to its year-end Nifty target.

Factors that will guide the markets this week

Factors that will guide the markets this week

Rediff.com18 May 2025

Stock markets will be mainly driven by quarterly earnings by corporates, foreign fund flows and global trends this week, analysts said.

USTR flags hurdles in medical device exports to India

USTR flags hurdles in medical device exports to India

Rediff.com2 Apr 2025

The USTR report, released just ahead of the US' April 2 deadline for implementing reciprocal tariffs, has also cited high tariffs and price caps, which have not increased in line with inflation, as key obstacles for US businesses.

Govt tells e-com firms to audit dark patterns, submit yearly reports

Govt tells e-com firms to audit dark patterns, submit yearly reports

Rediff.com30 May 2025

The government on Wednesday asked e-commerce platforms to conduct annual internal audits to make sure that they are not resorting to manipulative tactics to mislead consumers and prevent them from making right choices -- a technique commonly referred to as dark pattern -- and submit reports to the Department of Consumer Affairs (DoCA). It comes just a week after Uber was issued a notice by the Central Consumer Protection Authority (CCPA) over its "advance tip" feature.

Health care, pharma IPOs raise Rs 14,811 cr in 2024

Health care, pharma IPOs raise Rs 14,811 cr in 2024

Rediff.com23 Dec 2024

India's healthcare and pharmaceutical sectors raised Rs 14,811 crore through initial public offerings (IPOs) in 2024, the largest since 2019, driven by strong domestic demand amid expanding global opportunities. According to data, key contributors to the record fundraising included Sai Life Sciences (Rs 3,043 crore), IKS Health (Rs 2,498 crore), and Sagility India (Rs 2,107 crore).

Want To Study BPharm, Engineering In Europe?

Want To Study BPharm, Engineering In Europe?

Rediff.com11 Jul 2025

rediffGURU Sushil Sukhwani offers guidance about the best courses and colleges for an international education.

US drug shortage a shot in the arm for Indian pharmaceutical companies

US drug shortage a shot in the arm for Indian pharmaceutical companies

Rediff.com26 Jun 2023

Drug shortages in the US are at an all-time high, and price erosion has stabilised, which could benefit Indian pharmaceutical (pharma) companies with a US focus, according to analysts. Nuvama Research analysts said that US price erosion seems to have normalised to its old levels of 6-8 per cent and volumes are picking up with easing of inventory. Similarly, an ICICIdirect analyst noted: "Price erosion intensity has now moderated to a single digit and is expected to tone down a

Exports up 9% to $38.49 bn in Apr; trade deficit widens to 5-month high of $26.42 bn

Exports up 9% to $38.49 bn in Apr; trade deficit widens to 5-month high of $26.42 bn

Rediff.com16 May 2025

India's exports rose 9.03 per cent to $38.49 billion in April, the highest in six months, driven by healthy growth in sectors such as electronics and engineering goods, while the trade deficit widened to a five-month high of $26.42 billion. According to the commerce ministry data released on Thursday, imports increased by 19.12 per cent year-on-year to $64.91 billion in April due to a rise in shipments of crude oil and fertiliser.

What impact will US tariffs have on economies, sectors and markets?

What impact will US tariffs have on economies, sectors and markets?

Rediff.com29 Mar 2025

The sweeping tariffs proposed across sectors by US President Donald Trump are scheduled to be imposed starting April 2, with most analysts worried about their impact on companies, and in turn the financial markets. Recently, the US administration signaled that it will impose sectoral tariffs on energy, pharmaceuticals, semiconductors, agriculture, copper, and lumber.

These sectors will NOT face Trump's reciprocal tariffs: GTRI

These sectors will NOT face Trump's reciprocal tariffs: GTRI

Rediff.com3 Apr 2025

Essential and strategic items such as pharmaceuticals, semiconductors, copper, and energy products like oil, gas, coal and LNG are exempted from the 27 per cent import duty announced by the US on Wednesday, according to think tank GTRI.

US again puts India on 'priority watch list' for alleged IP rights' violations

US again puts India on 'priority watch list' for alleged IP rights' violations

Rediff.com29 Apr 2025

The US on Tuesday again placed India on its 'priority watch list' stating that New Delhi remains one of the world's most challenging major economies with respect to protection and enforcement of intellectual property (IP) rights.